Business Context and Reporting Period
This Form 8-K is a current report filed by Spero Therapeutics, Inc. on July 1, 2022. The filing addresses Item 5.02 regarding the approval of compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation details.
- CEO Cash Bonus: $254,000 (payable November 30, 2022).
- CEO Potential Equity Value: $508,000 (based on stock price at May 31, 2023).
- CFO Cash Bonus: $168,000 (payable November 30, 2022).
- CFO Potential Equity Value: $336,000 (based on stock price at May 31, 2023).
Material Changes
There are no material changes to financial performance or operations reported in this filing. The primary event is the Board's approval of retention awards for the Chief Executive Officer, Ankit Mahadevia, M.D., and the Chief Financial Officer, Satyavrat Shukla.
Guidance, Outlook, and Risks
The filing outlines specific performance criteria required for the Restricted Stock Units (RSUs) to vest by May 31, 2023. These criteria relate to:
- Pipeline execution.
- Business development.
- Financial stewardship.
Risks and Contingencies: The equity awards are contingent upon the executives remaining actively employed through May 31, 2023. If performance criteria are not met, the RSUs will lapse. The awards are subject to acceleration provisions only in the event of certain termination events following a change in control, limited to the extent previously determined eligible.
Investor Verification Checklist
- Verify the total cash outflow of $422,000 scheduled for November 30, 2022.
- Monitor the achievement of pipeline and business development milestones by May 31, 2023, which determine the issuance of up to $844,000 in equity value.
- Confirm continued employment of Dr. Mahadevia and Mr. Shukla through the vesting period.
- Review the specific definitions of "performance criteria" in the executives' employment agreements.